Skip to main content

Table 3 Adjusted Cox hazards regression models for specific opportunistic illnesses for patients who used combination antiretroviral therapy (N = 1878 individuals)

From: Predictors of opportunistic illnesses incidence in post combination antiretroviral therapy era in an urban cohort from Rio de Janeiro, Brazil

  Tuberculosis Esophageal candidiasis Cerebral Toxoplamosis PCP
  (N = 30) (N = 10) (N = 12) (N = 8)
  HR (CI) HR (CI) HR (CI) HR (CI)
Gender-Risk     
 Women Ref. Ref. Ref. Ref.
 Heterosexual men 0.85 (0.38–1.88) 0.15 (0.02–1.25) 1.46 (0.39–5.43) 0.81 (0.16–4.20)
 MSM 0.53 (1.89–1.58) 0.25 (0.05–1.42) 0.31 (0.05–2.00) 0.59 (0.08–4.16)
Age (per year) 1.02 (0.99–1.06) 0.93 (0.86–1.02) 0.91 (0.84–0.99) 1.07 (1.00–1.14)
Race/ethnicity     
 White Ref. Ref. Ref. Ref.
 Non-white 0.86 (0.39–1.88) 2.10 (0.43–10.29) 0.46 (0.14–1.51) 1.26 (0.27–5.87)
Educational level     
 0–8 years 2.08 (0.78–5.51) 0.89 (0.19–4.12) 1.22 (0.29–5.10) 0.38 (0.07–2.03)
 9+ years Ref. Ref. Ref. Ref.
Nadir CD4+ T lymphocyte (per 100 cells/mm3) 0.85 (0.63–1.15) 0.73 (0.42–1.25) 0.89 (0.59–1.33) 1.25 (0.83–1.90)
Opportunistic illness at enrollment 23.0 (9.60–55.2) 13.6 (2.93–63.3) 34.6 (8.50–141.4) 21.5 (2.86–162.1)
Time under cART (per year) 0.78 (0.63–0.97) 0.55 (0.29–1.03) 0.61 (0.39–0.96) 0.60 (0.33–1.08)
  1. PCP Pneumocystis jiroveci pneumonia, HR hazard ratio, CI 95 % confidence interval, MSM men who have sex with men
  2. Bold font implies statistically significant results assuming a 5 % significance threshold